Moolec Science SA (MLEC) Key Metrics
MLEC valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $1.2M
- Enterprise value
- $69.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 0.0
- Price / book
- 0.5 10-yr median 62.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.32
MLEC key metrics, FY2021–FY2025
Fiscal year ended June 30, 2025 · U.S. dollarsMLEC valuation Price multiples at each fiscal year-end price.
MLEC returns How much profit the business earns on the capital it uses.
MLEC per-share figures Results divided by the shares outstanding at year-end.
MLEC financial health Debt, liquidity and how easily interest is covered.
MLEC efficiency & capital use Working capital cycle and where the cash goes.
MLEC valuation history
MLEC returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MLEC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MLEC cash returned to shareholders
MLEC price vs earnings per share
MLEC key metrics
FY2021–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Market capitalization | $40.7M | $423.3M | $1.27B | $3.75B | $1.70B |
| Enterprise value | $278.6M | $432.6M | $1.27B | $3.75B | $1.70B |
| Price / sales | 0.1 | 75.3 | — | — | — |
| Price / book | — | 62.1 | 125.5 | — | 12.7 |
| EV / sales | 0.8 | 76.9 | — | — | — |
| EV / EBITDA | — | 30.6 | — | — | — |
| Earnings yield | −273.7% | −1.7% | −4.1% | −0.1% | −0.0% |
| Free cash flow yield | −73.9% | −2.2% | −0.6% | −0.1% | −0.0% |
| Dividend yield | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shareholder yield (dividends + buybacks) | 2.3% | 0.1% | 0.2% | 0.0% | — |
| Share price at fiscal year-end | $94.50 | $165.00 | $552.00 | $1,498.50 | $1,465.50 |
| Per share | |||||
| Revenue per share | $774.28 | $2.19 | $0.39 | $0.00 | $0.00 |
| Earnings per share | −$258.69 | −$2.85 | −$22.54 | −$1.81 | −$0.01 |
| Operating cash flow per share | −$56.75 | −$3.64 | −$3.27 | −$0.37 | −$0.01 |
| Free cash flow per share | −$69.87 | −$3.70 | −$3.35 | −$0.75 | −$0.01 |
| Cash per share | $20.94 | $2.10 | $1.23 | $0.43 | $0.29 |
| Book value per share | −$153.11 | $2.66 | $4.40 | $0.64 | $115.79 |
| Tangible book value per share | −$327.78 | −$0.94 | $0.58 | −$1.20 | $111.82 |
| Dividends per share | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Capex per share | $13.12 | $0.06 | $0.08 | $0.00 | $0.00 |
| Debt per share | $572.99 | $5.72 | $1.15 | $0.05 | $0.11 |
| Shares outstanding | 431K | 2.6M | 2.3M | 2.5M | 1.2M |
| Change in shares outstanding | −83.2% | +11.7% | −8.2% | +116.2% | — |
| Returns & profitability | |||||
| Return on equity (ROE) | — | −86.4% | −884.5% | −6.7% | −0.0% |
| Return on invested capital (ROIC) | −8.8% | −54.9% | −99.5% | −2.0% | −0.0% |
| Return on assets (ROA) | −93.1% | −24.9% | −348.2% | −6.3% | −0.0% |
| Return on tangible assets | −86.1% | −28.6% | −338.9% | −414.3% | −0.0% |
| Free cash flow margin | −9.0% | −168.6% | −849.7% | — | — |
| Financial health | |||||
| Total debt | $246.9M | $14.7M | $2.6M | $125,000 | $125,000 |
| Cash & short-term investments | $9.0M | $5.4M | $2.8M | $1.1M | $337,603 |
| Net debt | $237.9M | $9.3M | −$188,418 | −$956,808 | −$212,603 |
| Debt / equity | — | 2.15 | 0.26 | 0.08 | 0.00 |
| Debt / assets | 1.21 | 0.42 | 0.11 | 0.02 | 0.00 |
| Net debt / EBITDA | — | 0.66 | — | — | — |
| Current ratio | 0.13 | 1.69 | 0.42 | 0.27 | 0.67 |
| Quick ratio | 0.12 | 0.92 | 0.39 | 0.27 | 0.67 |
| Interest coverage | -0.3 | -7.8 | -41.6 | -805.9 | — |
| Working capital | −$204.9M | $5.6M | −$7.3M | −$3.0M | −$280,157 |
| Invested capital | $171.9M | $16.1M | $9.9M | $647,525 | $133.9M |
| Tangible asset value | −$158.1M | −$2.4M | $1.3M | −$3.0M | $129.5M |
| Net current asset value | −$256.4M | −$14.2M | −$8.6M | −$3.0M | −$3.9M |
| Graham net-net per share | −$609.24 | −$7.14 | −$4.18 | −$1.20 | −$3.41 |
| Capital allocation | |||||
| Dividends paid | $0 | $0 | $0 | $0 | — |
| Share buybacks (net) | $926,899 | $305,000 | $3.0M | — | — |
| Capex / revenue | 1.7% | 2.8% | 19.8% | — | — |
| Capex / depreciation | 0.25 | 0.01 | 1.47 | 0.00 | 0.00 |
| Stock-based compensation / revenue | 1.3% | 36.4% | 4,839.5% | — | — |
| R&D / revenue | 2.8% | 31.5% | 149.1% | — | — |
| SG&A / revenue | 34.5% | 127.6% | 5,239.0% | — | — |
| Efficiency | |||||
| Days sales outstanding | 11.7 | 103.0 | 341.0 | — | — |
| Days of inventory on hand | 7.1 | 238.9 | 81.1 | — | — |
| Days payables outstanding | 6.1 | 113.8 | 435.8 | — | — |
| Cash conversion cycle (days) | 12.7 | 228.1 | -13.6 | — | — |
| Receivables turnover | 31.17 | 3.55 | 1.07 | 0.00 | 0.00 |
| Payables turnover | 59.64 | 3.21 | 0.84 | 0.00 | — |
| Inventory turnover | 51.58 | 1.53 | 4.50 | — | — |
| Asset turnover | 2.79 | 0.19 | 0.06 | 0.00 | 0.00 |
| Average receivables | $10.7M | $1.6M | $845,637 | $144,944 | $289,888 |
| Average payables | $3.7M | $1.6M | $1.3M | $375,892 | $587,658 |
| Average inventory | $4.3M | $3.4M | $232,874 | $0 | — |
| Intangibles / total assets | 36.8% | 26.6% | 36.5% | 80.8% | 3.3% |
Computed from MLEC's annual financial statements (latest annual report filed December 29, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MLEC valuation and financial ratios
Moolec Science earned a return on invested capital of −8.8% in fiscal 2025. It ended the year with $246.9 million of debt and $9.0 million in cash and short-term investments, net debt of $237.9 million. It returned $0.9 million to shareholders: $0 in dividends and $0.9 million in share buybacks. The share count fell 62.8% from 1.2M to 431K over 4 years.
See the MLEC income statement, the MLEC chart for price history, or the MLEC stock overview for the latest quote and news.
MLEC key metrics FAQ
What is Moolec Science's ROIC?
Moolec Science's return on invested capital was −8.8% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Moolec Science have?
Moolec Science had total debt of $246.9 million at the end of fiscal 2025.
Does Moolec Science pay a dividend?
Moolec Science did not pay a dividend in fiscal 2025.
Does Moolec Science buy back its shares?
Yes. Moolec Science spent $0.9 million on net share repurchases in fiscal 2025 Shares outstanding changed −83.2% over the year, to 431K..
What is Moolec Science's free cash flow yield?
Moolec Science generated -$30.1 million of free cash flow in fiscal 2025, a free cash flow yield of −73.9% on its market value at year-end ($40.7 million).
What is Moolec Science's current ratio?
Moolec Science's current ratio was 0.13 at the end of fiscal 2025: current assets were 0.13 times current liabilities.